全文获取类型
收费全文 | 22773篇 |
免费 | 2064篇 |
国内免费 | 428篇 |
专业分类
耳鼻咽喉 | 90篇 |
儿科学 | 277篇 |
妇产科学 | 496篇 |
基础医学 | 1308篇 |
口腔科学 | 472篇 |
临床医学 | 4110篇 |
内科学 | 7485篇 |
皮肤病学 | 152篇 |
神经病学 | 668篇 |
特种医学 | 615篇 |
外国民族医学 | 1篇 |
外科学 | 2125篇 |
综合类 | 2106篇 |
一般理论 | 2篇 |
预防医学 | 2432篇 |
眼科学 | 266篇 |
药学 | 1975篇 |
8篇 | |
中国医学 | 439篇 |
肿瘤学 | 238篇 |
出版年
2024年 | 23篇 |
2023年 | 690篇 |
2022年 | 707篇 |
2021年 | 1513篇 |
2020年 | 1490篇 |
2019年 | 1463篇 |
2018年 | 1282篇 |
2017年 | 904篇 |
2016年 | 791篇 |
2015年 | 907篇 |
2014年 | 1606篇 |
2013年 | 2239篇 |
2012年 | 1106篇 |
2011年 | 1262篇 |
2010年 | 964篇 |
2009年 | 875篇 |
2008年 | 902篇 |
2007年 | 883篇 |
2006年 | 719篇 |
2005年 | 631篇 |
2004年 | 562篇 |
2003年 | 502篇 |
2002年 | 395篇 |
2001年 | 382篇 |
2000年 | 281篇 |
1999年 | 245篇 |
1998年 | 222篇 |
1997年 | 229篇 |
1996年 | 170篇 |
1995年 | 153篇 |
1994年 | 139篇 |
1993年 | 119篇 |
1992年 | 143篇 |
1991年 | 128篇 |
1990年 | 79篇 |
1989年 | 74篇 |
1988年 | 74篇 |
1987年 | 47篇 |
1986年 | 61篇 |
1985年 | 66篇 |
1984年 | 60篇 |
1983年 | 33篇 |
1982年 | 34篇 |
1981年 | 11篇 |
1980年 | 25篇 |
1979年 | 18篇 |
1978年 | 17篇 |
1977年 | 17篇 |
1976年 | 6篇 |
1974年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Mathew Vithayathil Scott Smith Mingyang Song 《International journal of cancer. Journal international du cancer》2023,152(6):1085-1094
Serrated polyps (SPs) are precursors to one-third of colorectal cancers (CRCs), with histological subtypes: hyperplastic polyps (HPs), sessile serrated lesions (SSLs) and traditional serrated adenomas (TSAs). The incidence of early-onset CRC before the age of 50 is increasing, with limited understanding of SPs in younger cohorts. Using a large colonoscopy-based cohort, we characterized epidemiologic profiles of SP subtypes, compared to conventional adenomas, with secondary analysis on early-onset polyps. Ninety-four thousand four hundred and twenty-seven patients underwent screening colonoscopies between 2010 and 2018. Demographic, endoscopic and histopathologic characteristics of each polyp subtype were described. High-risk polyps included SSLs ≥10 mm/with dysplasia and conventional adenomas ≥10 mm/with tubulovillous/villous histology/high-grade dysplasia. We examined polyp prevalence with age and compared early- (age < 50) and late-onset polyps (age ≥ 50). Eighteen thousand one hundred and twenty-five patients had SPs (4357 SSLs, 15 415 HPs, 120 TSAs) and 26 699 had conventional adenomas. High-risk SSLs were enriched in the ascending colon (44.1% vs 2.6-35.8% for other locations; P < .003). Early- and late-onset SPs had similar subsite distribution. Early-onset conventional adenomas were more enriched in the distal colon/rectum (51.8% vs 43.4%, P < .001). Multiple conventional adenomas were more represented in late-onset groups (40.8% vs 33.8%, P < .001), with no difference in SSLs. The prevalence of conventional adenomas/high-risk conventional adenomas increased continuously with age, whereas the prevalence of SSLs/high-risk SSLs was stable from age 40 years onwards. A higher proportion of women were diagnosed with early-onset than late-onset SSLs (62.9% vs 57.6%, P = .03). Conventional adenomas, SSLs, early- and late-onset polyps have distinct epidemiology. The findings have implications for improved colonoscopy screening and surveillance and understanding the etiologic heterogeneity of CRC. 相似文献
2.
3.
《Radiography》2022,28(2):353-359
Patient contact shielding has been in use for many years in radiology departments in order to reduce the effects and risks of ionising radiation on certain organs. New technologies in projection imaging and CT scanning such as digital receptors and automatic exposure control (AEC) systems have reduced doses and improved image consistency. These changes and a greater understanding of both the benefits and the risks from the use of shielding have led to a review of shielding use in radiology. A number of professional bodies have already issued guidance in this regard. This paper represents the current consensus view of the main bodies involved in radiation safety and imaging in Europe: European Federation of Organisations for Medical Physics, European Federation of Radiographer Societies, European Society of Radiology, European Society of Paediatric Radiology, EuroSafe Imaging, European Radiation Dosimetry Group (EURADOS), and European Academy of DentoMaxilloFacial Radiology (EADMFR). It is based on the expert recommendations of the Gonad and Patient Shielding (GAPS) Group formed with the purpose of developing consensus in this area. The recommendations are intended to be clear and easy to use. They are intended as guidance, and they are developed using a multidisciplinary team approach. It is recognised that regulations, custom and practice vary widely on the use of patient shielding in Europe and it is hoped that these recommendations will inform a change management program that will benefit patients and staff. 相似文献
4.
5.
6.
7.
XI Hui CHENG Guan Liang HU Fei Fei LI Song Nan DENG Xuan ZHOU Yong 《Biomedical and environmental sciences : BES》2022,35(3):206-214
Objective To explore associations between lipoprotein-associated phospholipase A2(Lp-PLA2) and the risk of cardiovascular events in a Chinese population, with a long-term follow-up.Methods A random sample of 2,031 participants(73.6% males, mean age = 60.4 years) was derived from the Asymptomatic Polyvascular Abnormalities Community study(APAC) from 2010 to 2011. Serum Lp-PLA2 levels were determined by enzyme-linked immunosorbent assay(ELISA). The composite endpoint was a combination of first-eve... 相似文献
8.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(3):301-310
Background and objectiveTo describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain.Material and methodsRetrospective, observational and multicentric study that included patients initiating treatment with evolocumab (from February 2016 to August 2018), in 15 Nephrology Units in Spain. The demographic and clinical characteristics of the patients, the lipid lowering treatment and the evolution of the lipid profiles between 24 weeks pre-initiation and 12 ± 4 weeks post-initiation of evolocumab were reviewed.ResultsSixty patients were enrolled: 53.3% women; mean (SD) age, 56.9 (12.8) years, 45.0% with familial hypercholesterolemia (FH) (5.0% homozygous and 40.0% heterozygous) and 65.0% with atherosclerotic cardiovascular (CV) disease. The mean (SD) eGFR was 62.6 (30.0) ml/min/1.73 m2 (51.7% of patients had eGFR < 60 ml/min/1.73 m2 [CKD stage > 2]), 50.0% had proteinuria (>300 mg/g) and 10.0% had nephrotic syndrome. Other CV risk factors were hypertension (75.0%), diabetes (25.0%), and smoking (21.7%). A 40.0% of patients were statin intolerant. At evolocumab initiation, 41.7% of patients were on a high-intensity statin, 18.3% on moderate intensity statin and 50.0% were receiving ezetimibe. Mean (SD) LDL-c at evolocumab initiation was 179.7 (62.9) mg/dL (53.4% of patients with LDL-c≥160 mg/dL and 29.3%≥190 mg/dL). After 12 weeks, evolocumab resulted in LDL-c reductions of 60.1%. At week 12, 90.0% of patients reached LDL-c levels <100 mg/dL, 70.0% <70 mg/dL, and 55.0% <55 mg/dL, while mean eGFR levels and statin use were remained stable.ConclusionIn Nephrology Units of Spain, evolocumab was predominantly prescribed in patients with FH, chronic renal disease (CRD>2) and secondary prevention, with LDL-c levels above those recommended by the guidelines. Evolocumab used in clinical practice significantly reduced the LDL-c levels in all patients included in the study. 相似文献
9.
10.